Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Invest New Drugs
; 39(6): 1641-1648, 2021 12.
Article
in En
| MEDLINE
| ID: mdl-34322775
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrimidines
/
Quinazolines
/
Squamous Cell Carcinoma of Head and Neck
/
Phosphoinositide-3 Kinase Inhibitors
/
Head and Neck Neoplasms
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: